1CM
NKTR icon

1492 Capital Management’s Nektar Therapeutics NKTR Stock Holding History

1492 Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-538
Closed -$394K – 96
2018
Q2 		$394K Sell
538
-11
-2% -$12.7K 0.28% 73
2018
Q1 		$875K Sell
549
-620
-53% -$799K 0.67% 43
2017
Q4 		$1.05M Sell
1,169
-1,585
-58% -$937K 0.82% 41
2017
Q3 		$992K Sell
2,754
-7
-0.3% -$2.19K 0.88% 35
2017
Q2 		$810K Sell
2,761
-46
-2% -$13.3K 0.71% 45
2017
Q1 		$988K Sell
2,807
-1
-0% -$225 0.77% 39
2016
Q4 		$517K Sell
2,808
-115
-4% -$23.4K 0.4% 63
2016
Q3 		$753K Sell
2,923
-185
-6% -$47.6K 0.62% 39
2016
Q2 		$663K Sell
3,108
-7,931
-72% -$1.77M 0.6% 42
2016
Q1 		$2.28M Sell
11,039
-1,001
-8% -$192K 1.93% 17
2015
Q4 		$3.04M Sell
12,040
-508
-4% -$104K 2.21% 14
2015
Q3 		$2.06M Buy
12,548
+8,678
+224% +$1.54M 1.47% 25
2015
Q2 		$726K Buy
3,870
+1,007
+35% +$173K 0.46% 60
2015
Q1 		$472K Buy
+2,863
New +$588K 0.27% 83

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

1492 Capital Management's NKTR Position: Q3 2018 in Review

1492 Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 538 shares — an estimated $394K sold.

1492 Capital Management first reported a position in NKTR in Q1 2015 and held it in 14 quarters. The position peaked at $3.04M in Q4 2015. 388 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • 1492 Capital Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • 1492 Capital Management sold 538 Nektar Therapeutics shares in Q3 2018, an estimated $394K.
  • 1492 Capital Management first reported a position in Nektar Therapeutics in Q1 2015 and held it in 14 quarters.
  • 1492 Capital Management's Nektar Therapeutics position peaked at $3.04M in Q4 2015.
  • 388 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on 1492 Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.